TRANSITION THERAPEUTICS TO ACQUIRE OUTSTANDING SHARES OF ALZHEIMER'S DISEASE FOCUSED ELLIPSIS NEUROTHERAPEUTICS INC.
Transition Therapeutics Inc., announced the signing of a Share Purchase Agreement
("Purchase Agreement") with the directors of Ellipsis Neurotherapeutics
Inc. ("ENI") pursuant to which Transition will offer to acquire all
the remaining outstanding shares of ENI. The key asset in this transaction is
ENI's lead molecule AZD-103, a disease modifying agent with the potential to
both reduce disease progression and improve symptoms such as cognitive function.